{
  "timestamp": "2025-10-04T23:43:01.997Z",
  "apiResponse": {
    "download_url": "/api/download_icf/?file=tmpntsd9sgt.docx",
    "generated_text": "{\n  \"Purpose of the Study\": \"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19.\",\n  \"Study Procedures\": \"The study will enroll a specified number of patients who are hospitalized with severe COVID-19 related Acute Respiratory Distress Syndrome. The exact number of patients and study duration are not provided in the extracted text.\",\n  \"Risks\": \"Known potential risks include risks of drawing blood and IV catheterization, as well as risks due to study treatments and risks to privacy.\",\n  \"Benefits\": \"The benefits of participating in the study may include access to investigational therapeutics aimed at treating severe illness from COVID-19, though specific benefits are not detailed in the extracted text.\"\n}",
    "log": [
      {
        "page": 1,
        "text_sample": "Protocol\nA Multicenter, Adaptive, \nRandomized, Blinded Controlled \nTrial of the Safety and Efficacy "
      },
      {
        "page": 2,
        "text_sample": "A Multicenter, Adaptive, Randomized, Blinded Controlled Trial  \nof the Safety and Efficacy of Invest"
      },
      {
        "page": 3,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 4,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 5,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 6,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 7,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 8,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 9,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 10,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 11,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 12,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 13,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 14,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 15,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 16,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 17,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 18,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 19,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 20,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 21,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 22,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 23,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 24,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 25,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 26,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 27,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 28,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 29,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 30,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 31,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 32,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 33,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 34,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 35,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 36,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 37,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 38,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 39,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 40,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 41,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 42,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 43,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 44,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 45,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 46,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 47,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 48,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 49,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 50,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 51,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 52,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 53,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 54,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 55,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 56,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 57,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 58,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 59,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 60,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 61,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 62,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 63,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 64,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 65,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 66,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 67,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 68,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 69,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 70,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 71,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 72,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 73,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 74,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 75,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 76,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 77,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 78,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 79,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      },
      {
        "page": 80,
        "text_sample": "Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Master Protocol \nVersion 3.0, 08 Mar"
      }
    ],
    "sections": {
      "Purpose of the Study": "A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19.",
      "Study Procedures": "The study will enroll a specified number of patients who are hospitalized with severe COVID-19 related Acute Respiratory Distress Syndrome. The exact number of patients and study duration are not provided in the extracted text.",
      "Risks": "Known potential risks include risks of drawing blood and IV catheterization, as well as risks due to study treatments and risks to privacy.",
      "Benefits": "The benefits of participating in the study may include access to investigational therapeutics aimed at treating severe illness from COVID-19, though specific benefits are not detailed in the extracted text."
    }
  },
  "generatedText": "{\n  \"Purpose of the Study\": \"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19.\",\n  \"Study Procedures\": \"The study will enroll a specified number of patients who are hospitalized with severe COVID-19 related Acute Respiratory Distress Syndrome. The exact number of patients and study duration are not provided in the extracted text.\",\n  \"Risks\": \"Known potential risks include risks of drawing blood and IV catheterization, as well as risks due to study treatments and risks to privacy.\",\n  \"Benefits\": \"The benefits of participating in the study may include access to investigational therapeutics aimed at treating severe illness from COVID-19, though specific benefits are not detailed in the extracted text.\"\n}",
  "generatedTextRaw": "\"{\\n  \\\"Purpose of the Study\\\": \\\"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19.\\\",\\n  \\\"Study Procedures\\\": \\\"The study will enroll a specified number of patients who are hospitalized with severe COVID-19 related Acute Respiratory Distress Syndrome. The exact number of patients and study duration are not provided in the extracted text.\\\",\\n  \\\"Risks\\\": \\\"Known potential risks include risks of drawing blood and IV catheterization, as well as risks due to study treatments and risks to privacy.\\\",\\n  \\\"Benefits\\\": \\\"The benefits of participating in the study may include access to investigational therapeutics aimed at treating severe illness from COVID-19, though specific benefits are not detailed in the extracted text.\\\"\\n}\""
}